(1) "Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery. In the trial, this benefit was seen at one month and continued virtually unchanged throughout the six month blinded study period."
(2) "The primary measure of efficacy in the study was the difference in off-medication motor scores between the treated and sham groups on the Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 (Motor section), which has long been the standard for clinical assessment in Parkinson's disease. All subjects were evaluated at baseline as well as one, three and six months after undergoing surgery."
(3) The study investigators continue to further evaluate the detailed data and we look forward to its publication or presentation," said Clark A. Johnson, President and Chief Executive Officer of the Company. "Today's news is also important validation for our ongoing development of other technologies for neurological and psychiatric diseases, including our advanced pre-clinical program in epilepsy. Given these results, we would look to pursue a strategic transaction which will maximize value for the Company."
*Guess we just have to wait for the actual trial specifics regarding actual scores reflecting degree of improvement in the treatment arm...damn! My sister has PD, would love to have more specific information to pass on.
Congrats to all longs who got in before the spike. Company appears to have roughly 9 months worth of cash, so obviously a capital raise of some sort is in order. Luckily, with such a low float, NRGX could easily double the shares and still be in excellent shape share wise.
The results were evident within 1 month of treatment...amazing. Those here who are familiar with the P-1 trial...can you comment on durability and degree of response from that trial?
